AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales

Key Stats for AbbVie StockCurrent Price: $285. 64Target Price (Mid): ~$364Street Target: ~$285Potential Total Return: ~27%Annualized IRR: ~6% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?AbbVie (ABBV) now lets Crohn’s patients start Skyrizi at home, and when that reaches sales depends on how fast insurers move.